Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders

Stopped early · Not applicable

Conditions studied: Rectal Cancer

In brief

The current standard of care for rectal cancer has diminished local recurrence and enhanced survival. Quality of life, however, remains poor for many patients and the probability of distant recurrence is high. In this study, we will attempt to reduce the distant recurrence rate and improve quality of life by making changes in the timing and administration of chemotherapy and radiation and doing less invasive rectal surgery when indicated.

Key facts

Study ID

NCT03941366

Run by

Henry Ford Health System

People needed

15

Starts

2016-02-26

Expected to finish

2025-04-01

Last updated by the study team

2026-07-23

Who can join

Age: 18 and older, up to 95. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Diagnosis of rectal invasive adenocarcinoma
• Tumor in the low or mid rectum (up to 11 cm from the anal verge)
• Clinical stage T3/N0-N1M0. Patients with low T2 who will need abdominal perineal resection are also eligible.
• Clinical staging will be estimated based on the combination of the following assessments:
• Physical examination by the primary surgeon
• Computed Tomography or Positron Emission Tomography/Computed Tomography scan of chest, abdomen and pelvis
• Pelvic MRI and endoscopic ultrasound

You may not qualify if…

• Less than 18 years of age
• Do not complete informed consent
• Pregnant women

Where it is running

• Ascension St. John Hospital — Detroit, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.